CGEM — Cullinan Therapeutics Share News
0.000.00%
Last trade - 00:00- $960.17m
- $625.63m
Brief: Cullinan Oncology Announces The Appointment Of David Ryan To Its Board Of Directors
Brief: Cullinan Oncology Significantly Increases Ownership Stake In Its MICA Subsidiary Which Holds Worldwide Rights To Clinical-Stage Novel Monoclonal Antibody CLN-619
Brief: Cullinan Oncology Appoints Jacquelyn Sumer As Chief Legal Officer
Brief: Cullinan Oncology Provides Corporate Update, Reports Q2 Results
Brief: Cullinan Oncology And Taiho Pharmaceutical Complete Agreement For Strategic Collaboration To Jointly Develop And Commercialize Cln-081/Tas6417
Pains and gains for cancer drugmakers ahead of industry meet
Pains and gains for cancer drugmakers ahead of industry meet
Brief: Cullinan Oncology Reports Q1 Loss Of 27 Cents Per Share
develop lead drug
Brief: Cullinan And Taiho To Jointly Develop And Commercialize Cln-081/Tas6417 And Taiho's Acquisition Of Cullinan Pearl
Brief: Cullinan Oncology Announces Clinical And Regulatory Update For CLN-081 In NSCLC EGFR Exon 20 Patients
U.S. RESEARCH ROUNDUP-Digitalbridge Group, Joann, Park Ohio Holdings
Brief: Cullinan Oncology Provides Corporate Update And Reports Q4
Brief: Cullinan Oncology Forms Strategic Collaboration Agreement With Mount Sinai To Advance Oral HPK1 Protein Degrader For Cancer Treatment
U.S. STOCKS ON THE MOVE-Pinterest, AVROBIO, Sea Ltd, JD.com, Hoth Therapeutics
U.S. STOCKS ON THE MOVE-Plus Therapeutics, Allena Pharam, Avrobio, Nine Energy
Cullinan Oncology jumps as cancer treatment gets breakthrough therapy tag
Brief: FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Brief: Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 In NSCLC EGFR Exon 20 Patients